Clinical Trials Directory

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

If you choose to join this study, we will ask you questions about:

• Your life at home
• Your life at school
• Your medical needs

This study includes people who may or may not receive radiation therapy as part of their normal medical care. The radiation treatment is not part of the research and is the usual treatment decided by their doctors. People who receive radiation therapy will give small blood samples before starting radiation, at the end of radiation, and about six months later. People who do not receive radiation therapy will give blood samples after surgery and again about eight months later. The blood samples will only be used for research. They will help researchers learn more about how treatment affects the body, but the results will not be used to make decisions about a participant's medical care.

The study wants to see which type of care works better at lowering the chance of heart problems. One type of care is based on the Cleerly CAD stage, which uses pictures of the heart to guide treatment. The other type of care uses a persons risk factors, like high blood pressure or high cholesterol. The study will also look at other health outcomes, such as kidney and heart problems and deaths. Researchers will check how safe each type of care is and if either one causes any harms.

We are doing this study to find out how safe and effective it is to give people with recurrent glioblastoma two infusions of an experimental drug called lerapolturev (the study drug) in residual disease (within tumor margins) after surgery. After these two doses, we will give further doses of the study drug as injections in the subcutaneous area (under the skin) around the lymph nodes of the head and neck. We also want to know how well the study drug works compared to lomustine, which is a standard form of chemotherapy (drug used to kill cancer cells).

We are doing this study to find out if a personalized exercise program designed for lung cancer patients can help with recovery from lung surgery. The study's exercise program is delivered over the phone.

We created this registry for people with rare breast tumors to help us learn more about them and how to better treat people in the future.

We are doing this study to find out if an experimental drug called ravulizumab (the study drug) is a safe and effective option to prevent or reduce the severity of delayed graft function after people with end-stage kidney disease (ESKD) get a kidney transplant.